A Retrospective Analysis of 72 patients on prior efalizumab subsequent to the time of voluntary market withdrawal in 2009

Journal of Drugs in Dermatology

Volumn 13, Issue 6, 2014, Pages 712-718

  Prater, Elizabeth Farley ^a   Day, Antoinette ^b   Patel, Mahir ^c   Menter, Alan ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFALIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TREATMENT FAILURE; FAMILY HISTORY; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PUSTULOSIS PALMOPLANTARIS; QUALITY OF LIFE; REVIEW; SEX RATIO; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; AGE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG RECALL; MIDDLE AGED; PATHOLOGY; PSORIASIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

AGE FACTORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; SAFETY-BASED DRUG WITHDRAWALS; SEX FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84903382694     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol, 2007;25: 35-46.
2. Farber EM, N.L., Psoriasis, ed. M.H. Roenigk HH. 1998, New York: Dekker. 107-57.
3. Finlay AY, Kelly SE. Psoriasis-an index of disability. Clin Exp Dermatol. 1987;12:8-11.
4. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-85.
5. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-64. (Pubitemid 351509657)
6. Burmester GR, Panaccione R, Lacerda AP et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72(4):517-24.
7. Gordon, KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized control trial. JAMA 2003;290:3072-80.
8. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13. (Pubitemid 37448923)
9. Van Lingen RG, Kover JEM, Van de Kerkhof PCM et al. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies. Br J Dermatol. 2008;159:91-96. (Pubitemid 351874502)
10. Pettey A, Balkrishnan R, and Rapp S et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: Implications for clinical practice. J Am Acad Dermatol. 2003;49:271-275. (Pubitemid 36951276)
11. Eriksson MO, Hagforsen EH, Lundin IP et al. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390-398. (Pubitemid 28145503)
12. Hagforsen E, Edvinsson M, Nordlind K et al. Exoression of nicotinic receptors in the skin of patients with palmoplantar pustulosis. Br J Dermatol. 2002;146:383-391. (Pubitemid 34603809)
13. Bhushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double blind, placebo-controlled study. Br J Dermaol. 2001;145:546-553.
14. Chalmers R, Hollis S, Leonardi-Bee J et al. Interventions for chronic palmoplantar pustulosis. Cochrane Database of Systematic Reviews 2006;1.
15. Wozel G, Vitez L, Meurer M. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab. Acta Dermatoven. 2008;17:133-136.
16. Gottlieb A, Hamilton T, and Caro I et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. J Am Acad Dermatol. 2006;54:154-63.
17. Leondardi C, Menter A, Gottlieb AB et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol. 2008;158(5):1107-16. (Pubitemid 351521472)
18. Leonardi CL, Toth D, Cather JC et al. A review of malignancies during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology. 2006;213:204-14. (Pubitemid 44567830)
19. Foley P, Freeman M, Gebauer K et al. Long-term efalizumab therapy for patients with moderate-to-severe chronic plaque psoriasis: results from an Austrailian expanded access program. Int J Dermatol. 2009;48:1376-84.
20. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol. 2007;156(S2):7-1.
21. Constanzo A, Peris K, Talamonti M. Long-term treatment of plaque psoriasis with eflaizumab: an Italian experience. Br J Dermatol. 2007;156(S2)17-23. (Pubitemid 46434870)
22. Korman BD, Tyler KL, and Korman NJ. Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression: A Cautionary Tale for Dermatologists. Arch Dermatol. 2009;145:937-940.
23. Farley E, Masrour S, McKey J, Menter A. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009:60(6);1024-31.
24. Ammoury A, El Sayed F, Dhaybi R, Bazex J. Palmoplantar pustulosis should not be considered as a variant of psoriasis. J Eur Acad Dermatol Vernero.l 2008;22:392-3. (Pubitemid 351247449)
25. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans, J et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol. 2003;120:627-32. (Pubitemid 36344006)
26. Kingo K, Mossner R, Koks S, Ratsep R, Kruger U, Vasar E, et al. Association analysis of IL9, IL20, and IL24 of genes in palmoplantar pustulosis. Br J Dermatol. 2007;156:646-52. (Pubitemid 46452358)
27. Marrakchi S, Guigue P, Renshaw BR, Smahi A et al. Interleukin-36 receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011:365(7):620-8.
28. Setta-Kaffetzi N, Navarini AA, Barker JN et al. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol. 2013:133(5):-1366-9.
29. Kanazawa N, Nakamura T, Mikta N, and Furukawa F. Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasis. J Dermatol. 2013:July Epub ahead of print.